Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: US FDA Clears Kisqali For Breast Cancer And Keytruda In Lymphoma, But Turns Down AZ's ZS-9 Again

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Keeping Track: Immuno-Oncology Racks Up More Approvals; Bar Still Too High For Advair Generics

The latest drug development news and highlights from our US FDA Performance Tracker.

FDA's NDA And BLA Approvals: Kisqali, Voriconazole

Original new drugs and biologics recently approved by US FDA.

US FDA Strategy On Abuse-Deterrent Opioids Needs Rethinking, Panelists Say

Deterring intravenous abuse over other routes of abuse should be agency's priority, some advisory committee members say during discussion of abuse patterns and risks with Endo’s reformulated Opana ER.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS120245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel